Introduction
============

Post-operative cognitive dysfunction (POCD) is generally defined as a decline in cognitive function that occurs in patients after anesthesia and surgery when compared to their preoperative cognitive status. POCD occurs in approximately 10% of all surgical patients and 40% of elderly patients at age 65 and older ([@B28]), and is associated with increased mortality, decreased quality of life and increased dependency ([@B41]). Although the cause of POCD remains to be determined, general anesthesia alone is now being recognized as a potentially significant risk to cognitive performance at both extremes of age. A large body of experimental studies as well as some retrospective clinical evidence have showed that exposure to anesthetics could be detrimental to cognitive development in young subjects, and might also contribute to cognitive impairment in the elderly ([@B15]; [@B39]). Of note, anesthesia-induced cognitive impairment may depend on age, anesthetic agent, dosage, duration, and number of exposures ([@B13]; [@B38]; [@B8]). Additionally, the presence of chronic diseases may also increase the likelihood of developing cognitive impairment or cause exacerbation of pre-existing cognitive decline after anesthesia ([@B10]; [@B50]; [@B52]).

Diabetes mellitus (DM) is an increasingly common medical condition affecting approximately 347 million people worldwide, and about 90% of them have type 2 DM ([@B31]). An estimated 25% of diabetic patients will require surgery ([@B31]). Recent evidence has suggested that DM is associated with cognitive dysfunction and is an important risk factor for dementia ([@B17]; [@B18]; [@B26]; [@B56]).

Sevoflurane is one of the most commonly used volatile anesthetic agents for the maintenance of anesthesia in surgical patients, including patients with type 2 DM ([@B5]). Sevoflurane has favorable clinical characteristics such as rapid pharmacokinetics and lack of airway irritability. Previous studies have demonstrated that a moderate duration of sevoflurane (2--3% for 2 or 4 h) does not induce cognitive impairment in both adult and aged animals ([@B7]; [@B38]). These studies, however, have been conducted in animals under physiological conditions and clinical studies of POCD exclude patients who are already cognitively impaired. To date, however, the influence of sevoflurane on cognitive dysfunction under diabetic conditions has not been examined. The present study sought to determine whether sevoflurane might exaggerate cognitive dysfunction in a rat model of type 2 DM and if so, to explore a possible underlying mechanism, focusing on sevoflurane-induced change in neuroinflammation that has been implicated in pathophysiology of cognitive impairment ([@B29]; [@B24]; [@B54]; [@B56]).

Materials and Methods {#s1}
=====================

Animals
-------

All experiments and procedures were approved by the Animal Care and Use Committee at Shandong University, and performed in accordance with the guidelines of the Animal Care and Use Committee at Shandong University. All efforts were made to minimize animal suffering and the number of animals used in the study.

Twelve-week-old male diabetic Goto--Kakizaki (GK) rats and age-matched male non-diabetic Wistar rats were purchased from SLAC Laboratory Animal, Co., Ltd. (Shanghai, China). GK rat is a genetic non-obese model of type 2 DM with relatively stable hyperglycemia, early hyperinsulinemia and insulin resistance and later insulin deficiency ([@B47]). This model is prone to developing cognitive deficits and learning impairments along aging and has been considered to be one of the useful animal models for studying the pathogenesis of type 2 DM and its neurological complications ([@B29]; [@B24]; [@B14]). A previous study has shown that GK rats display cognitive dysfunction at 7--8 months of age, we therefore used 9-month-old GK rats to examine the influence of sevoflurane on cognitive dysfunction under diabetic conditions in our study. All Animals were maintained in environmentally controlled rooms and were granted free access to standard rat chow and tap water.

Experimental Design
-------------------

At 9 months of age, hyperglycemia was confirmed via tail vein blood samples, the animals were then assigned to the following experimental groups (*n* = 20 rats per group): (1) Wistar control rats (Wistar + CON), (2) Wistar rats treated with sevoflurane (Wistar + SEV), (3) GK control rats (GK + CON), and (4) GK rats treated with sevoflurane (GK + SEV).

Sevoflurane exposure was performed as previously described ([@B52]). Briefly, rats were placed in a temperature controlled chamber with two interfaces that were connected to an anesthesia machine and a multi-gas monitor, respectively. For rats assigned to sevoflurane exposure groups, 2.6% sevoflurane was provided by a humidified 30% O~2~ carrier gas from a calibrated vaporizer for 4 h. Rats assigned to control groups were also placed in the same chamber except no sevoflurane was provided (sham exposure). The concentrations of sevoflurane, O~2~ and CO~2~ in the chamber were continuously monitored by a gas analyzer (Datex Ohmeda, Mississauga, ON, Canada). The rectal temperature was maintained at 37°C during the experiment. Blood pressure (BP) and heart rate were measured hourly with a CODA Monitor (Kent Scientific, Corp., Torrington, CT, United States). Arterial blood gasses were measured in some rats (*n* = 6 for each group) before and immediately after sevoflurane exposure.

Ten rats from each group were used for open field test and trace-fear conditioning 7 days after sevoflurane exposure to determine the short-term effect of sevoflurane on cognitive function. The rest of animals from each group (*n* = 10 rats per group) were used for Morris water maze (MWM) 5 months after sevoflurane exposure (at the age of 14 months) to determine long-term effect of sevoflurane on cognitive function. Immediately after trace-fear conditioning or MWM assessments, animals were sacrificed to collect brains and blood for molecular and biochemical analyses or perfused transcardially with 4% paraformaldehyde for immunofluorescent study.

Open-Field Test
---------------

General locomotor activity was assessed by open-field test as previously described ([@B10]). Each rat was placed in an open field apparatus. The floor of the apparatus was subdivided into 25 blocks (9″ square) with thin white stripes, and animal activity was recorded via a digital camera. The number of line crossings and rearings performed in 5 min time period was scored. The apparatus was cleaned with 75% alcohol and rinsed with water to avoid the presence of olfactory cues following each test.

Trace Fear Conditioning
-----------------------

Hippocampal-dependent learning and memory tasks were assessed by trace fear conditioning (TFC) as previously described ([@B20]; [@B11]) with minor modifications. TFC training and testing were carried out in a room with overhead fluorescent light and a ventilation fan providing background noise (65 db). During the training, rats were placed in the experimental chamber (Med Associates, Inc.) and allowed to adapt to this context for 3 min, after which they received three consecutive pairs of tone (80 dB, 5 kHz, 20 s) and foot shock (0.8 mAmp, 2 s) with an empty trace interval of 20 s and a break between each pair of 3 min.

Sevoflurane exposure was performed within 30 min after training. Memory of the learned fear was assessed 7 days later by returning the animals into the original chamber without tone and shock. Behavior for each animal was recorded and scored every 5 s during the 5 min observation period. A percentage was calculated using the formula 100 × f/n, where f is the number of freezing events (absence of all movement except for respiration) per animal and n is the total number of observations per animal.

Morris Water Maze
-----------------

Five months after sevoflurane exposure, spatial and related forms of learning and memory were assessed by MWM, as previously described ([@B53]). Briefly, a 10-cm diameter platform was placed 1 cm above the water surface in a circular tank (diameter, 150 cm; depth, 50 cm). A flag was placed on the platform to increase its visibility. Rat was gently released in the water and emerged from the water onto the platform within 120 s. If the rat failed to find the platform, place the rat on the raised platform and allow it to stay there for 20 s before being removed from the pool. A different platform location was used for each subsequent trial. This cueing procedure enables the rats to acknowledge that they can escape the water by finding a platform.

After cueing procedure, the platform in the third quadrant was submerged 1.5 cm below the water level and the place trials were carried out for 4 days to examine the rats' ability to obtain spatial information. A black curtain was used to surround the pool to eliminate confounding visual cues. Each rat received four trials per day in each of the four quadrants of the swimming pool. On each trial, rats were placed into the water facing the pool wall, and allowed to search for the platform for a maximum of 120 s and stay on the platform for 20 s before being removed from the pool. A rat that failed to find the platform within 120 s was guided to the platform and stayed there for 20 s. For all training trials, the time required for a rat to reach the hidden platform (escape latency), swimming speed and swimming path were automatically digitized and recorded. The average of four trials performed each day for each animal was calculated as the escape latency.

The day after the completion of the hidden platform training, probe trials were conducted to examine whether the rats had developed a spatial bias for the former platform quadrant. The platform in the third quadrant was removed from the pool and rats were allowed to swim for 120 s in any of the four quadrants of the swimming pool. The number of crossings over the original position of the platform and the percent time spent in each quadrant were recorded.

Western Blot Analysis
---------------------

Protein levels of pro-inflammatory cytokines in the hippocampus were analyzed by western blot as previously described ([@B53]). Briefly, the hippocampus was quickly dissociated from brain and homogenized in an ice-cold lysis buffer with protease inhibitor. The protein concentration was determined by a Bradford assay using BSA as the standard. Samples were electrophoresed on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels, and the gels were transferred to polyvinylidene difluoride (PVDF) membranes. After blocking for 1 h in 5% non-fat dry milk, the membranes were incubated with primary antibodies to tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and β-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, United States) at 4°C overnight. Membranes were then washed and incubated at room temperature with HRP-conjugated second antibody (Santa Cruz Biotechnology, Inc.) for 1 h. The enhanced chemiluminescence detection system (Amersham) was applied to visualize the immunoreactive bands, and the band densities were analyzed with ImageJ software (National Institutes of Health). All data were normalized by β-actin.

Immunofluorescent Study
-----------------------

Rats were perfused transcardially with heparinized saline followed by 4% paraformaldehyde. Brains were removed and post-fixed overnight in 4% paraformaldehyde at 4°C and then immersed in 30% sucrose. Serial coronal sections of 20-μm thickness were cut using a cryostat. Immunofluorescent staining was performed as previously described with modifications ([@B35]; [@B23]). Briefly, brain sections were incubated by 0.5% H~2~O~2~ for 30 min followed by 10% normal horse serum for 60 min to facilitate antibody penetration. After washing three times, the sections were incubated with anti-rat CD11b primary antibody (clone OX-42) (1:100, Chemicon, Temecula, CA, United States) at 4°C overnight. Subsequently, the sections were incubated for 2 h in an anti-mouse secondary antibody (Alex Fluor 488, 1:200; Invitrogen, Carlsbad, CA, United States) followed by washing three times. Immunofluorescent staining for microglia was visualized with a confocal microscope (Zeiss LSM 510; Carl Zeiss, Thornwood, NY, United States). The number of activated microglia, defined by stronger immunofluorescent staining for the marker CD11b (clone OX-42), the presence of a clearly enlarged soma and marked changes in the appearance of the processes ([@B35]), were counted in several 0.2 mm × 0.2 mm squares and expressed as a percentage of the total number of microglia.

Biochemical Assays
------------------

Blood samples were collected and placed on ice immediately. Plasma was isolated by centrifugation at 2500 *g* for 15 min at 4°C. Plasma glucose levels were measured using a glucose analyzer (Prestige Smart System). Plasma insulin levels were measured by commercially available rat ELISA kit (Invitrogen, Camarillo, CA, United States).

Statistical Analysis
--------------------

Data were analyzed using a two-way ANOVA. Factors were identified as diabetes (Wistar and GK) and sevoflurane exposure (CON and SEV). Tukey's *post hoc* test was subsequently used for comparisons between groups. In MWM test, the number of original platform (the third quadrant) crossings and the percent time spent in the third quadrant were analyzed using a two-way ANOVA followed by Tukey's *post hoc* test. Data are presented as mean ± SE. Values were considered statistically significant when *P* \< 0.05.

Results
=======

Sevoflurane Induces Short-Term Memory Decline in GK Rats But Not in Wistar Rats
-------------------------------------------------------------------------------

To exclude possible locomotor dysfunction that might confound the cognitive assessment, open-field test was conducted to assess spontaneous activity prior to cognitive test. There were no differences among four experimental groups in the number of rearings (**Figure [1A](#F1){ref-type="fig"}**) and the number of crossings (**Figure [1B](#F1){ref-type="fig"}**).

![Baseline locomotion assessed by open field test in type 2 diabetic Goto--Kakizaki (GK) rats and non-diabetic Wistar rats at 9 months of age. There were no differences among four experimental groups in the number of rearings **(A)** and the number of crossings **(B)**. Data are presented as mean ± SE (*n* = 10 for each group).](fphar-08-00886-g001){#F1}

Short-term memory was assessed by the percentage of time spent freezing when rats were placed in the same TFC training context 7 days after sevoflurane exposure. Notably, GK control rats exhibited significantly less freezing when compared with Wistar control rats at 9 months of age \[*F*(1,36) = 65.05, *P* \< 0.01\] (**Figure [2](#F2){ref-type="fig"}**), indicating that type 2 DM causes impairment in hippocampal-dependent memory at this time point. Sevoflurane exposure did not alter freezing in Wistar rats but further reduced freezing in GK rats, compared with respective control groups \[*F*(1,36) = 5.13, *P* \< 0.05\].

![Fear conditioning in type 2 diabetic Goto--Kakizaki (GK) rats and non-diabetic Wistar rats 7 days after sevoflurane (SEV) or sham (control, CON) exposure. Freezing times was shorter in GK + CON rats than Wistar +CON rats and was further reduced in GK + SEV rats. Of note, freezing times was similar between two Wistar groups. Data are presented as mean ± SE (*n* = 10 for each group). ^∗^*P* \< 0.05 vs. respective Wistar rats; ^†^*P* \< 0.05 vs. GK + CON rats.](fphar-08-00886-g002){#F2}

Sevoflurane-Induced Cognitive Decline in GK Rats Is Persistent
--------------------------------------------------------------

Five months after sevoflurane exposure, place trial revealed that there was no difference across four experimental groups in swimming speed throughout 4 consecutive days (**Figure [3A](#F3){ref-type="fig"}**), suggesting that the motor ability of rats was not affected by type 2 DM or sevoflurane. The escape latency to the submerged platform did not differ between Wistar control rats and Wistar rats that received sevoflurane exposure (**Figure [3B](#F3){ref-type="fig"}**). In contrast, both groups of GK rats exhibited significantly longer latency to find the submerged platform than the Wistar rats on the last two trials \[day 4: *F*(1,36) = 26.88, *P* \< 0.01\], and the GK rats that received sevoflurane exposure had much higher latency than GK control rats \[day 4: *F*(1,36) = 5.204, *P* \< 0.05\].

![The ability of spatial information acquisition assessed by Place trial in type 2 diabetic Goto--Kakizaki (GK) rats and non-diabetic Wistar rats 5 months after sevoflurane (SEV) or sham (control, CON) exposure. There was no difference across four experimental groups in swimming speed throughout 4 consecutive days **(A)**. However, both groups of GK rats took longer to locate the submerged platform than Wistar rats on the last two trials, and the GK + SEV rats spent more time to find the submerged platform than GK + CON rats **(B)**. Data are presented as mean ± SE (*n* = 10 for each group). ^∗^*P* \< 0.05 vs. respective Wistar rats; ^†^*P* \< 0.05 vs. GK+CON rats.](fphar-08-00886-g003){#F3}

On the probe trial, no differences between the two Wistar groups were observed for the number of platform crossings (**Figure [4A](#F4){ref-type="fig"}**) and the percent time spent in third quadrant (**Figure [4B](#F4){ref-type="fig"}**). Compared with Wistar rats, both groups of GK rats displayed significantly reduced number of platform crossings \[*F*(1,36) = 56.31, *P* \< 0.01\] and percent time spent in third quadrant \[*F*(1,36) = 35.31, *P* \< 0.01\]. Moreover, the reductions in the number of platform crossings \[*F*(1,36) = 4.71, *P* \< 0.05\] and the percent time spent in third quadrant \[*F*(1,36) = 4.25, *P* \< 0.05\] were greater in GK rats receiving sevoflurane exposure than GK control rats.

![The memory retention capabilities assessed by Probe trial in type 2 diabetic Goto--Kakizaki (GK) rats and non-diabetic Wistar rats 5 months after sevoflurane (SEV) or sham (control, CON) exposure. The number of original platform (the third quadrant) crossings **(A)** and the percent time spent in the third quadrant **(B)** were reduced in both groups of GK rats than Wistar rats. Moreover, the number of platform crossings and the percent time spent in the third quadrant were less in GK + SEV rats than those in GK + CON rats. Data are presented as mean ± SE (*n* = 10 for each group). ^∗^*P* \< 0.05 vs. respective Wistar rats; ^†^*P* \< 0.05 vs. GK+CON rats.](fphar-08-00886-g004){#F4}

Sevoflurane Aggravates Hippocampal Inflammation and Microglia Activation in GK Rats
-----------------------------------------------------------------------------------

Given the findings that sevoflurane exposure induced cognitive decline in GK rats, we next investigated the possible underlying mechanism. Pro-inflammatory cytokines, particularly IL-1β, TNF-α and IL-6, are associated with cognitive impairment ([@B33]; [@B12]; [@B43]; [@B32]). We therefore assessed the effects of the sevoflurane exposure on the levels of IL-1β, TNF-α, and IL-6 in the hippocampus, a brain structure that is critical for learning and memory. Western blot analysis revealed that the protein levels of IL-1β, TNF-α, and IL-6 in the hippocampus, measured at 7 days or 5 months after sevoflurane exposure, were not different between the two Wistar groups (**Figure [5](#F5){ref-type="fig"}**). However, the protein levels of IL-1β, TNF-α, and IL-6 in the hippocampus in both groups of GK rats were increased at 7 days after sevoflurane exposure \[IL-1β: *F*(1,20) = 76.65, *P* \< 0.01; TNF-α: *F*(1,20) = 144.8, *P* \< 0.01; IL-6: *F*(1,20) = 114.6, *P* \< 0.01\] and remained at high levels 5 months after sevoflurane exposure \[IL-1β: *F*(1,20) = 78.49, *P* \< 0.01; TNF-α: *F*(1,20) = 96.06, *P* \< 0.01; IL-6: *F*(1,20) = 121.7, *P* \< 0.01\], compared with Wistar rats. Of note, the increases in the protein levels of these pro-inflammatory cytokines were greater in GK rats receiving sevoflurane exposure than GK control rats at both time points \[7 days: IL-1β: *F*(1,20) = 10.26, *P* \< 0.01; TNF-α: *F*(1,20) = 14.02, *P* \< 0.01; IL-6: *F*(1,20) = 15.87, *P* \< 0.01; 5 months: IL-1β: *F*(1,20) = 18.08; *P* \< 0.01; TNF-α: *F*(1,20) = 12.09, *P* \< 0.01; IL-6: *F*(1,20) = 10.71, *P* \< 0.01\].

![Representative Western blots **(A)** and quantitative comparison of protein levels for pro-inflammatory cytokines IL-1β **(B)**, TNF-α **(C)**, and IL-6 **(D)** in the hippocampus in type 2 diabetic Goto--Kakizaki (GK) rats and non-diabetic Wistar rats 7 days and 5 months after sevoflurane (SEV) or sham (control, CON) exposure. The levels of pro-inflammatory cytokines in the hippocampus were higher in GK + CON rats than those in Wistar + CON rats at both time points and were further increased in GK + SEV rats. Data are presented as mean ± SE (*n* = 6 for each group). ^∗^*P* \< 0.05 vs. respective Wistar rats at the same time point; ^†^*P* \< 0.05 vs. GK + CON rats at the same time point.](fphar-08-00886-g005){#F5}

Microglia are the primary immune cells in the central nervous system and can be activated by a variety of stimuli, including anesthetics ([@B35]; [@B2]; [@B51]). Activated microglia are now recognized to be major sources of proinflammatory cytokines and chemokines within the central nervous system ([@B2]). We therefore examined the effects of the sevoflurane exposure on microglia activation using immunofluorescent study. As shown in **Figure [6](#F6){ref-type="fig"}**, there are few activated microglia, as defined by strong CD11b immunoreactivity, an enlarged soma, fewer and shorter processes, in the hippocampus in two groups of Wistar rats at 7 days or 5 months after sevoflurane exposure. In contrast, activated microglia were clearly observed in the hippocampus in both groups of GK rats at each time point. Moreover, the number of activated microglia was significantly greater in GK rats receiving sevoflurane exposure when compared with GK control rats \[7 days: effect of diabetes: *F*(1,12) = 87.07, *P* \< 0.01; effect of SEV: *F*(1,12) = 13.65, *P* \< 0.01; 5 months: effect of diabetes: *F*(1,12) = 73.5, *P* \< 0.01; effect of SEV: *F*(1,12) = 15.89, *P* \< 0.01\].

![Microglia activation in the hippocampus in type 2 diabetic Goto--Kakizaki (GK) rats and non-diabetic Wistar rats 7 days and 5 months after sevoflurane (SEV) or sham (control, CON) exposure. **(A)** Representative photomicrographs showing CD11b-immunoreactive microglia in the hippocampus in each group. **(B)** Representative photomicrographs showing non-activated and activated microglia in the hippocampus. **(C)** Quantitative analysis of activated microglia in the hippocampus in each group. The number of activated microglia in the hippocampus was higher in GK + CON rats than that in Wistar + CON rats at both time points and was further increased in GK + SEV rats. Data are presented as mean ± SE (*n* = 4 for each group). ^∗^*P* \< 0.05 vs. respective Wistar rats at the same time point; ^†^*P* \< 0.05 vs. GK + CON rats at the same time point.](fphar-08-00886-g006){#F6}

Sevoflurane Does Not Alter the Metabolic, Hemodynamic, and Physiologic Parameters in Both Wistar and GK Rats
------------------------------------------------------------------------------------------------------------

GK control rats exhibited significantly smaller weight gain \[*F*(1,28) = 88.35, *P* \< 0.01\] during the experimental period as compared to Wistar control rats. Plasma glucose concentrations \[*F*(1,28) = 204.6, *P* \< 0.01\] were significantly higher but plasma insulin levels \[*F*(1,28) = 7.44, *P* \< 0.01\] were significantly lower in GK control rats than in Wistar control rats at 9 and 14 months of age (**Table [1](#T1){ref-type="table"}**). These data indicate that GK rats develop diabetes with insulin deficiency during the experimental period. Sevoflurane exposure did not affect body weight, plasma glucose concentrations, and insulin levels in either Wistar or GK rats.

###### 

Metabolic parameters.

                                               Wistar+CON    Wistar+SEV    GK+CON           GK+SEV
  -------------------------------------------- ------------- ------------- ---------------- ----------------
  **Variables measured at age of 9 months**                                                 
  Body weight (g)                              436 ± 5       430 ± 8       362 ± 7^∗^       357 ± 5^∗^
  Glucose (mg/dL)                              113 ± 2       118 ± 3       235 ± 10^∗^      239 ± 8^∗^
  Insulin (μg/L)                               2.81 ± 0.32   2.79 ± 0.40   1.25 ± 0.28^∗^   1.23 ± 0.36^∗^
  **Variables measured at age of 14 months**                                                
  Body weight (g)                              472 ± 6       468 ± 10      374 ± 5^∗^       371 ± 9^∗^
  Glucose (mg/dL)                              125 ± 4       120 ± 7       218 ± 9^∗^       212 ± 6^∗^
  Insulin (μg/L)                               3.24 ± 0.37   3.30 ± 0.41   0.87 ± 0.10^∗^   0.85 ± 0.11^∗^

Data are presented as mean ± SE (

n

= 6--10 for each group).

∗

P

\< 0.05 versus respective Wistar rats at the same time point.

Before sevoflurane exposure, mean BP \[*F*(1,28) = 18.61, *P* \< 0.01\] was significantly increased in GK control rats than in Wistar control rats, however, heart rate, the acidity (pH), arterial carbon dioxide tension (PaCO~2~), arterial oxygen tension (PaO~2~), and arterial oxygen saturation (SaO~2~) was similar between two control groups (**Table [2](#T2){ref-type="table"}**). Notably, sevoflurane exposure did not alter any of these parameters in either Wistar or GK rats. These data excluded the possibility that the molecular and behavioral changes observed in the study were due to hemodynamic or physiologic side effects of sevoflurane.

###### 

Hemodynamic and physiologic parameters before (0 h) and 4 h after sevoflurane exposure.

               MBP (mmHg)   HR (beat/min)   pH            PaCO~2~ (mmHg)   PaO~2~ (mmHg)   SaO~2~ (%)
  ------------ ------------ --------------- ------------- ---------------- --------------- ------------
  **0 h**                                                                                  
  Wistar+CON   100 ± 2      329 ± 18        7.41 ± 0.05   38.2 ± 3.1       163 ± 12        98.6 ± 2.2
  Wistar+SEV   101 ± 4      332 ± 15        7.40 ± 0.04   40.1 ± 3.5       162 ± 17        98.1 ± 3.9
  GK+CON       119 ± 5^∗^   330 ± 11        7.39 ± 0.05   39.7 ± 3.0       166 ± 19        98.5 ± 2.7
  GK+SEV       121 ± 4^∗^   335 ± 13        7.40 ± 0.04   40.4 ± 3.3       160 ± 14        98.3 ± 3.0
  **4 h**                                                                                  
  Wistar+CON   97 ± 5       320 ± 16        7.39 ± 0.06   38.5 ± 3.9       162 ± 15        98.8 ± 3.3
  Wistar+SEV   99 ± 3       328 ± 20        7.38 ± 0.05   39.1 ± 3.7       161 ± 12        98.2 ± 3.4
  GK+CON       120 ± 6^∗^   327 ± 14        7.41 ± 0.05   39.2 ± 3.4       163 ± 16        98.6 ± 3.6
  GK+SEV       117 ± 5^∗^   325 ± 19        7.39 ± 0.04   40.0 ± 3.5       165 ± 18        98.5 ± 4.2

MBP, mean blood pressure; HR, heart rate; PaCO

2

, arterial carbon dioxide tension; PaO

2

, arterial oxygen tension; SaO

2

, arterial oxygen saturation. Data are presented as mean ± SE (

n

= 6--10 for each group),

∗

P

\< 0.05 versus respective Wistar rats at the same time point.

Discussion
==========

The major findings of this study are as follows: (1) sevoflurane exposure induces exaggerated and persistent cognitive decline in type 2 diabetic GK rats, whereas it has no effects on cognitive function in Wistar rats; (2) sevoflurane exposure further increases expression of proinflammatory cytokines and activation of microglia in the hippocampus in GK rats but not in Wistar rats. Taken together, these data suggest that type 2 DM increases sensitivity and susceptibility to the insult from sevoflurane exposure, which aggravates neuroinflammation in the hippocampus, contributing to the acute cognitive decline and the persistence of cognitive impairment.

In the behavioral paradigms that we used to interrogate cognitive domains of learning and memory, we found that Wistar control rats and Wistar rats that received sevoflurane did not differ in either TFC 7 days after sevoflurane exposure or in the MWM 5 months after sevoflurane exposure. This finding is consistent with recent reports that a moderate duration of sevoflurane exposure did not impair acquisition learning or memory in both young adult and aged rats ([@B7]; [@B38]). Several experimental studies have shown that sevoflurane induces neurodegenerative symptoms including apoptosis, inflammation, and Aβ accumulation in the hippocampus, resulting in impairment of both short-term and long-term cognitive function ([@B16]; [@B44]; [@B49]), especially in aged animals ([@B44]). The discrepancy of these results may be ascribed to the differences in animal species and age, the dosage of anesthetic, and/or the time points of the performance of the cognitive tests. Interestingly, our data showed that GK control rats, when compared with Wistar control rats, had less freezing in the TFC test at 9 months of age, longer latency to find the submerged platform as well as reduced number of platform crossings and percent time spent in third quadrant in the MWM test at the end of experiments, indicating impairment in their learning abilities and memory capabilities. These findings are in agreement with previous studies showing that the development of type 2 DM may causes cognitive dysfunction ([@B29]; [@B24]; [@B54]), which is associated with an increased risk of developing all forms of dementia, including vascular dementia and Alzheimer's disease ([@B1]; [@B21]). Importantly, our data showed that GK rats receiving sevoflurane exhibited both an early exacerbation of memory decline as well as a persistent deterioration in both learning and memory, when compared with GK control rats. Of note, non-cognitive factors that could have contributed to the behavioral assessments, such as altered spontaneous movement in TFC or the swimming speed in MWM, were not significantly different among four experimental groups. Collectively, these findings demonstrate that a moderate duration of sevoflurane exposure has no effect on cognitive function under physiological conditions, but it leads to exacerbation of the acute cognitive decline and the persistence of cognitive impairment under type 2 diabetic conditions. To our knowledge, this is the first study to determine the influence of type 2 DM on anesthetic-induced cognitive impairment.

Although several mechanisms have been suggested to be associated with cognitive dysfunction, accumulating evidence indicates that microglial activation and subsequent neuroinflammation play major roles in the development of cognitive dysfunction. Microglial cells are the resident macrophages in the central nervous system and have been demonstrated to play an important role in the brain's innate immunity and neuroinflammatory processes ([@B3]). Although microglia have a beneficial healing effect, activation of microglia is also considered to be toxic to the neighboring neurons via generating cytotoxic mediators including proinflammatory cytokines IL-1β, TNF-α, and IL-6 ([@B6]; [@B34]). Indeed, microglial activation and increased inflammatory cytokines in the brain are deeply involved in the cognitive dysfunction associated with various neurodegenerative disorders including Parkinson's disease, Alzheimer's disease, multiple sclerosis, and type 2 DM ([@B30]; [@B40]; [@B22]; [@B37]; [@B34]; [@B48]). Moreover, recent studies have demonstrated that surgery or anesthetics can induce microglial activation and neuroinflammation, contributing to cognitive impairment ([@B45], [@B46]; [@B44]; [@B34]). Interventions that reduce microglial activation and neuroinflammation in the brain can attenuate surgery- or anesthetic-induced cognitive impairment ([@B25]; [@B44]; [@B34]; [@B46]). Our data revealed that there were no differences in expression of proinflammatory cytokines IL-1β, TNF-α, and IL-6 and the number of activated microglia in the hippocampus between Wistar control rats and Wistar rats receiving sevoflurane 7 days or 5 months after sevoflurane exposure. However, compared with Wistar control rats, GK control rats exhibited significant increases in expression of proinflammatory cytokines and the number of activated microglia in the hippocampus at both time points. Moreover, expression of proinflammatory cytokines and the number of activated microglia in the hippocampus were further augmented in GK rats receiving sevoflurane compared with GK control rats. These molecular data were consistent with behavioral findings, suggesting that microglia-mediated neuroinflammation in the hippocampus contributes to cognitive dysfunction in type 2 DM, and that sevoflurane exposure induces exacerbation of the cognitive impairment in type 2 diabetic rats due to aggravation of neuroinflammation in the hippocampus.

The mechanisms by which sevoflurane aggravates neuroinflammation in the hippocampus of type 2 diabetic rats remain unclear. In this study, rats received sevoflurane at 9 months of age which could be considered as middle adulthood. We speculate that neuroinflammation may be prevented by anti-inflammatory counteregulatory mechanisms that maintain normal brain function in non-diabetic animals at this time point. The anti-inflammatory mechanisms in the brain may involve anti-inflammatory external signals (including anti-inflammatory cytokines, transforming growth factor-β, IL-10 and IL-1 receptor antagonist) and intracellular mediators (including endogenous cytoprotective genes or peroxisome proliferator-activated receptors) that may be expressed or activated in the brain in response to proinflammatory stimuli to prevent the inflammatory process and the injury ([@B42]). Under diabetic conditions, these anti-inflammatory external signals or mediators may be impaired or down-regulated, resulting in increased susceptibility to proinflammatory stimuli (including sevoflurane) and subsequent aggravation of neuroinflammation. Notably, sevoflurane-induced aggravation of neuroinflammation in the hippocampus of GK rats was observed even 5 months after sevoflurane exposure. This observation suggests that, under diabetic conditions, sevoflurane exposure might cause permanent changes in some key regulators of proinflammatory gene expression, such as the transcription factor nuclear factor-kappa B. Further studies are needed to elucidate the underlying mechanisms.

Insulin in the brain has been suggested to play an important role in promoting learning and memory function ([@B55]). For example, intranasal insulin administration has been demonstrated to improve glucose uptake and age-related cognitive decline in older people and aged animals ([@B36]; [@B27]). Additionally, intranasal insulin administration improves memory function, augments synaptic proteins, and significantly reduces microglia-mediated inflammation in the hippocampus in Alzheimer's disease or traumatic brain injury in animals ([@B9]; [@B4]). Moreover, a recent study showed that sevoflurane administration caused severe hepatic insulin resistance in a canine model ([@B19]). Insulin resistance induced by sevoflurane might also happen in the brain. In the present study, GK control rats showed significantly lower levels of plasma insulin when compared with Wistar control rats. Thus, we could not exclude the possibility that the cognitive decline observed in GK rats or exaggeration of cognitive dysfunction induced by sevoflurane were partly due to reduced insulin levels or increased insulin resistance in the brain.

With the increasing prevalence of type 2 diabetic patients undergoing surgery, and the increased risk of complications associated with type 2 DM, the appropriate perioperative assessment and management are necessary. The present study demonstrates that anesthetic sevoflurane induces exaggerated and persistent cognitive decline in a type 2 diabetic rat model probably by aggregating hippocampal inflammation. The findings from this study may provide useful information regarding clinical anesthetic choice for type 2 diabetic patients in the future.
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